Breaking News Instant updates and real-time market news.

CNCE

Concert Pharmaceuticals

$27.68

-0.35 (-1.25%)

07:07
01/12/18
01/12
07:07
01/12/18
07:07

FDA grants Fast Track Designation to Concert Pharmaceuticals' CTP-543

Concert Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Fast Track designation for CTP-543, a novel, oral Janus kinase inhibitor for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss. Concert is conducting a multi-center, double-blind, randomized, placebo-controlled Phase 2a trial to evaluate the safety and efficacy of CTP-543 in adults with moderate-to-severe alopecia areata.

CNCE Concert Pharmaceuticals
$27.68

-0.35 (-1.25%)

04/05/17
STFL
04/05/17
NO CHANGE
Target $31
STFL
Buy
Concert weakness a buying opportunity, says Stifel
Stifel analyst Adam Walsh said he believes the clinical tablet appearance issue that Concert Pharmaceuticals blamed for the delay in the start of its alopecia areata trial should be relatively easy to fix and only result in a minor delay. He continues to project U.S. approval and launch in FY20 and recommends shares be bought on related weakness. Walsh keeps a Buy rating and $31 price target on Concert shares.
05/17/17
STFL
05/17/17
NO CHANGE
Target $31
STFL
Buy
Resolution of Concert clinical hold should take quarter 'at most,' says Stifel
After Concert Pharmaceuticals announced that that FDA has placed the company's CTP-543 Phase 2 trial for alopecia areata on clinical hold, Stifel analyst Adam Walsh noted that no safety concerns were highlighted and that Concert already has the data of interest in-house, leading him to believe that the resolution of the hold will take a quarter "at most." The analyst, who still expects Concert to initiate and enroll the trial in 2017 and continues to project U.S. approval and launch in FY20, recommends buying on weakness and keeps a Buy rating and $31 price target on Concert shares.
07/24/17
HCWC
07/24/17
INITIATION
Target $20
HCWC
Buy
Concert Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started Concert Pharmaceuticals with a Buy rating, stating that recent lifting of a clinical hold on CTP-543 removed an overhang and cleared the path for Phase 2a readout next year. The analyst, who is bullish on the long-term potential of CTP-543 in alopecia areata, set a $20 price target on Concert shares.
12/19/17
UBSW
12/19/17
NO CHANGE
Target $34
UBSW
Buy
Concert Pharmaceuticals price target raised to $34 from $22 at UBS
UBS analyst Jeffrey Hung raised his price target on Concert Pharmaceuticals to $34 from $22 to reflect higher than expected demand for novel alopecia treatments. He continues to see a substantial opportunity for its alopecia treatment and increased his launch assumptions. The analyst also pointed to the company's clinical candidates that demonstrate the strategic value of the platform and pipeline optionality. Hung reiterated his Buy rating on Concert Pharmaceuticals shares.

TODAY'S FREE FLY STORIES

HURN

Huron

$38.30

0.65 (1.73%)

05:57
05/22/18
05/22
05:57
05/22/18
05:57
Conference/Events
Huron management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 12

    Jun

TOL

Toll Brothers

$43.60

0.43 (1.00%)

05:57
05/22/18
05/22
05:57
05/22/18
05:57
Earnings
Toll Brothers reports Q2 EPS 72c, consensus 76c »

Reports Q2 revenue $1.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

WWE

WWE

$57.86

6.37 (12.37%)

05:56
05/22/18
05/22
05:56
05/22/18
05:56
Conference/Events
WWE management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

WD

Walker & Dunlop

$56.10

1.07 (1.94%)

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Conference/Events
Walker & Dunlop management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 31

    May

BUD

AB InBev

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Upgrade
AB InBev rating change  »

AB InBev upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$201.75

2.8 (1.41%)

, BAYRY

Bayer

$0.00

(0.00%)

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

MMM

3M

$201.75

2.8 (1.41%)

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$228.74

3.73 (1.66%)

BIIB

Biogen

$277.69

-2.66 (-0.95%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

TEVA

Teva

$21.09

-0.14 (-0.66%)

UTHR

United Therapeutics

$104.12

-2.2 (-2.07%)

VCYT

Veracyte

$6.45

(0.00%)

VRTX

Vertex

$156.15

-1.09 (-0.69%)

NBRV

Nabriva Therapeutics

$4.54

-0.89 (-16.39%)

GILD

Gilead

$67.63

-0.38 (-0.56%)

GSK

GlaxoSmithKline

$40.05

0.005 (0.01%)

HRC

Hill-Rom

$90.70

0.12 (0.13%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

CELG

Celgene

$74.69

-3.7 (-4.72%)

JAZZ

Jazz Pharmaceuticals

$166.01

-1.59 (-0.95%)

ISRG

Intuitive Surgical

$463.18

4.3 (0.94%)

INSM

Insmed

$26.34

-2.16 (-7.58%)

REGN

Regeneron

$296.58

-5.29 (-1.75%)

OCX

OncoCyte

$2.50

-0.05 (-1.96%)

FGEN

FibroGen

$52.55

1.45 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 20

    Oct

  • 20

    Dec

CCJ

Cameco

$11.38

0.015 (0.13%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Downgrade
Cameco rating change  »

Cameco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$38.17

0.77 (2.06%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Conference/Events
Teradyne management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 30

    May

RTN

Raytheon

$213.95

2.88 (1.36%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Downgrade
Raytheon rating change  »

Raytheon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$11.96

-0.41 (-3.31%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Conference/Events
Syros Pharmaceuticals management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SPSC

SPS Commerce

$71.88

0.11 (0.15%)

05:53
05/22/18
05/22
05:53
05/22/18
05:53
Conference/Events
SPS Commerce management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 29

    May

  • 12

    Jun

RDCM

Radcom

$19.65

0.25 (1.29%)

05:52
05/22/18
05/22
05:52
05/22/18
05:52
Conference/Events
Radcom management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 24

    May

  • 29

    May

INFO

IHS Markit

$51.60

0.13 (0.25%)

05:52
05/22/18
05/22
05:52
05/22/18
05:52
Upgrade
IHS Markit rating change  »

IHS Markit upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$30.89

-2.66 (-7.93%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTM

Quantum

$3.62

-0.06 (-1.63%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Conference/Events
Quantum management to meet with Lake Street »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

FITB

Fifth Third

$30.89

-2.66 (-7.93%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTEX

OpenText

$34.10

0.1 (0.29%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Conference/Events
OpenText management to meet with Benchmark »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

NVEE

NV5 Global

$60.60

0.6 (1.00%)

05:50
05/22/18
05/22
05:50
05/22/18
05:50
Conference/Events
NV5 Global management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 09

    Jun

  • 12

    Jun

  • 13

    Jun

M

Macy's

$34.60

0.63 (1.85%)

05:49
05/22/18
05/22
05:49
05/22/18
05:49
Upgrade
Macy's rating change  »

Macy's upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCR

NCR Corp.

$31.30

0.11 (0.35%)

05:49
05/22/18
05/22
05:49
05/22/18
05:49
Conference/Events
NCR Corp. management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

, PFE

Pfizer

$35.79

0.15 (0.42%)

05:44
05/22/18
05/22
05:44
05/22/18
05:44
Hot Stocks
Spark Therapeutics, Pfizer announce data SPK-9001 ongoing Phase 1/2 trial »

Spark Therapeutics (ONCE)…

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

PFE

Pfizer

$35.79

0.15 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

FMC

FMC Corporation

$91.30

-0.22 (-0.24%)

05:41
05/22/18
05/22
05:41
05/22/18
05:41
Hot Stocks
FMC Corporation awarded contract for two fertilizer plants in India »

TechnipFMC, in consortium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$5.17

0.05 (0.98%)

05:40
05/22/18
05/22
05:40
05/22/18
05:40
Hot Stocks
Sprint partners with Scopeworker on multi-billion dollar 5G depoloyment »

Scopeworker announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSHD

Goosehead Insurance

$16.19

0.12 (0.75%)

05:39
05/22/18
05/22
05:39
05/22/18
05:39
Initiation
Goosehead Insurance initiated  »

Goosehead Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMAR

Smartsheet

$20.00

0.14 (0.70%)

05:38
05/22/18
05/22
05:38
05/22/18
05:38
Initiation
Smartsheet initiated  »

Smartsheet initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.